Coriolis Pharma, a globally operating service provider and one of the world leaders in formulation research and development of biopharmaceuticals and vaccines, announced the opening of its new ATMP development facilities under biosafety level S2 (BSL2 / S2).
After one year of re-construction, the new facilities in close proximity to Coriolis’ headquarters in Martinsried will significantly increase Coriolis’ capabilites for ATMP development. Formulation development for ATMPs, including cell culture activities, particle characterization, particle identification and forensic, analytical ultracentrifugation and a lyophilization development center will be available all under biosafety level 2, for Coriolis’ clients and partners.
“The new location with innovative labs and offices will be able to accommodate in the future more than 100 scientific employees,” said Dr. Michael Wiggenhorn, CEO of Coriolis Pharma.” With this expansion, we will meet the increasing demand for formulation development and analytical characterization of ATMPs.”
Advanced therapy medicinal products (ATMPs) are booming, but ATMP formulations are still far from advanced. Similar to mRNA vaccines, ATMPs either have a very short shelf life (hours to days) or require (ultra) cold storage conditions. A tailored formulation development program, also exploring lyophilization as an option, can remarkably improve this situation.
Already in 2018, Coriolis started strengthening its scientific expertise and services for ATMPs with a dedicated formulation unit for ATMPs and scientific collaborations that resulted in several peer-reviewed scientific publications. The opening of the new facilities marks the next step in the organic growth of the company.
“Having all our S2 activities in a dedicated and tailored facility increases the efficiency of our work procedures and creates a knowledge-hub for our ATMP projects,” explained Dr. Gerhard Sax, Business Unit Manager ATMP. “But what excites me the most is that we now have enough space to test and implement even more new and emerging technologies right under S2.”